Conduit Pharmaceuticals Inc. has entered into a strategic services agreement with formulation development CDMO Agility Life Sciences to develop new solid oral-dosage form products of its autoimmune pipeline for use in future clinical trials.

Conduit has developed a series of novel, advantageous solid forms of all its autoimmune pipeline assets, each protected by newly established composition-of-matter intellectual property (IP). Leveraging Agility’s extensive formulation expertise, this collaboration will focus on utilizing these proprietary forms to develop enhanced oral dosage forms for each asset. These dosage forms, designed with patient preferences and disease-specific needs in mind, are intended to allow Conduit to maximize the market potential of each asset while being underpinned by robust composition of matter IP.

As part of its focus on acquiring Phase 2-ready assets, Conduit’s pipeline includes several candidates that already have clinically tested oral formulations. This enables the Company to efficiently advance into Phase 2 trials using existing data packages. In parallel with ongoing autoimmune clinical trial plans, Conduit will work with Agility to develop enhanced proprietary oral dosage formulations for each asset. This dual-track approach is intended to strengthen market protection, enhance market value, and optimize the positioning of each asset for future licensing opportunities.